CSL Impacted by Launch Delays, Vaccine Fatigue, Says Jefferies

MT Newswires Live

Nov 11, 2025

CSL (ASX:CSL) will likely take time to rerate due to the impact of vaccine fatigue after the COVID-19 pandemic and lack of growth in its specialty product segment, according to a Sunday note from Jefferies.

Jefferies believes most of CSL's businesses operate in a logical and still underdeveloped market with room to grow.

The investment firm said that the share price continues to look "too cheap."

Jefferies noted that the European Union launch of the company's flu vaccine called aTIVc is now expected to be around fiscal 2028, with the US release delayed even further due to policy changes.

Jefferies reaffirmed its buy rating on CSL and lowered its price target to AU$237 from AU$240.

The company's shares rose almost 1% in recent Tuesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582674338"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582674338\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582674338?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 10:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582674338","market":"sg","top_or_hot":-1,"title":"CSL Impacted by Launch Delays, Vaccine Fatigue, Says Jefferies","media":"MT Newswires Live","content":"<html><body><p> CSL (ASX:CSL) will likely take time to rerate due to the impact of vaccine fatigue after the COVID-19 pandemic and lack of growth in its specialty product segment, according to a Sunday note from Jefferies.</p><p>Jefferies believes most of CSL's businesses operate in a logical and still underdeveloped market with room to grow.</p><p>The investment firm said that the share price continues to look \"too cheap.\"</p><p>Jefferies noted that the European Union launch of the company's flu vaccine called aTIVc is now expected to be around fiscal 2028, with the US release delayed even further due to policy changes.</p><p>Jefferies reaffirmed its buy rating on CSL and lowered its price target to AU$237 from AU$240.</p><p>The company's shares rose almost 1% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL Impacted by Launch Delays, Vaccine Fatigue, Says Jefferies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL Impacted by Launch Delays, Vaccine Fatigue, Says Jefferies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-11 10:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CSL (ASX:CSL) will likely take time to rerate due to the impact of vaccine fatigue after the COVID-19 pandemic and lack of growth in its specialty product segment, according to a Sunday note from Jefferies.</p><p>Jefferies believes most of CSL's businesses operate in a logical and still underdeveloped market with room to grow.</p><p>The investment firm said that the share price continues to look \"too cheap.\"</p><p>Jefferies noted that the European Union launch of the company's flu vaccine called aTIVc is now expected to be around fiscal 2028, with the US release delayed even further due to policy changes.</p><p>Jefferies reaffirmed its buy rating on CSL and lowered its price target to AU$237 from AU$240.</p><p>The company's shares rose almost 1% in recent Tuesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4086","symbol_name":"建筑产品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2582674338","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582674338","pubTimestamp":1762827056,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CSL (ASX:CSL) will likely take time to rerate due to the impact of vaccine fatigue after the COVID-19 pandemic and lack of growth in its specialty product segment, according to a Sunday note from Jeff","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4086":"建筑产品","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","CSL":"卡莱尔伙伴","BK7067":"生物科技","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","BK7508":"医药生物股","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK7501":"新冠治疗股","BK7511":"ESG概念","CSL.AU":"CSL LIMITED"},"translate_title":"杰富瑞表示，CSL受到发布延迟和疫苗疲劳的影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":1.5,"CSL":1.5},"content_text":"CSL (ASX:CSL) will likely take time to rerate due to the impact of vaccine fatigue after the COVID-19 pandemic and lack of growth in its specialty product segment, according to a Sunday note from Jefferies.Jefferies believes most of CSL's businesses operate in a logical and still underdeveloped market with room to grow.The investment firm said that the share price continues to look \"too cheap.\"Jefferies noted that the European Union launch of the company's flu vaccine called aTIVc is now expected to be around fiscal 2028, with the US release delayed even further due to policy changes.Jefferies reaffirmed its buy rating on CSL and lowered its price target to AU$237 from AU$240.The company's shares rose almost 1% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}